Posted on December 18, 2020 by Sitemaster
Earlier today, the US Food and Drug Administration (FDA) approved relugolix, (Orgovyx, from Myovant Sciences), the first, oral luteinizing hormone releasing hormone (LHRH) receptor antagonist for the treatment of adult patients with advanced prostate cancer. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: antagonist, GnRH, LHRH, Myovant, Orgovyx, relugolix | 6 Comments »
Posted on October 21, 2010 by Sitemaster
According to a media release from the U.S. Food and Drug Administration (FDA) yesterday, the agency has asked manufacturers of the class of drugs known as luteinizing hormone-releasing hormone (LHRH) or gonadotropin-releasing hormone (GnRH) agonists to include warnings about risk for cardiovascular disease and diabetes in product labeling for these drugs. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: agonist, cardiovascular, GnRH, LHRH, metabolic, risk, side effect | 3 Comments »
Posted on October 9, 2010 by Sitemaster
When all the drugs in the same class have the same general clinical impact, this is known as a “class effect.” As an example, all statins (hydroxymethylglutaryl–coenzyme A reductase inhibitors) will lower risk for certain types of cardiovascular event because they lower levels of cholesterol. That is a “class effect.” … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment, Uncategorized | Tagged: agonist, antagonist, GnRH, LHRH | 5 Comments »
Posted on May 3, 2010 by Sitemaster
For many years it has been understood by specialists that hormonal treatment of prostate cancer patients with luteinizing hormone releasing hormone (LHRH) agonists — also known as gonadatropin releasing hormone or GnRH agonists — is associated with metabolic side effects that include risks for cardiovascular disease and diabetes. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: agonist, androgen deprivation therapy, cardiovascular, GnRH, LHRH, metabolic, side effect | 1 Comment »
THE "NEW" PROSTATE CANCER INFOLINK 